| |  Online-Ressource |
|---|
| Verfasst von: | Schlenzka, Jana [VerfasserIn]  |
|---|
| | Möhler, Thomas [VerfasserIn] |
|---|
| | Kipriyanov, Sergey M. [VerfasserIn] |
|---|
| | Kornacker, Martin [VerfasserIn] |
|---|
| | Benner, Axel [VerfasserIn] |
|---|
| | Bähre, Alexandra [VerfasserIn] |
|---|
| | Stassar, Marike J. J. G. [VerfasserIn] |
|---|
| | Schäfer, Holger [VerfasserIn] |
|---|
| | Little, Melvyn [VerfasserIn] |
|---|
| | Goldschmidt, Hartmut [VerfasserIn] |
|---|
| | Cochlovius, Björn [VerfasserIn] |
|---|
| Titel: | Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B cell lymphoma |
|---|
| Verf.angabe: | Jana Schlenzka, Thomas M. Moehler, Sergey M. Kipriyanov, Martin Kornacker, Axel Benner, Alexandra Bähre, Marike J. J. G. Stassar, Holger J. Schäfer, Melvyn Little, Hartmut Goldschmidt and Björn Cochlovius |
|---|
| E-Jahr: | 2004 |
|---|
| Jahr: | [October 2004] |
|---|
| Umfang: | 5 S. |
|---|
| Illustrationen: | Diagramme |
|---|
| Fussnoten: | Gesehen am 25.02.2022 |
|---|
| Titel Quelle: | Enthalten in: Anti-cancer drugs |
|---|
| Ort Quelle: | Hagerstown, Md. : Lippincott Williams & Wilkins, 1990 |
|---|
| Jahr Quelle: | 2004 |
|---|
| Band/Heft Quelle: | 15(2004), 9 vom: Okt., Seite 915-919 |
|---|
| ISSN Quelle: | 1473-5741 |
|---|
| Abstract: | Combining different treatment strategies offers the possibility of improving treatment results for cancer patients. The aim of our study was therefore to investigate the combination of treatment of established s.c. human B non-Hodgkin's lymphoma in severe immune deficient mice using a recombinant bispecific CD19×CD16 diabody (targeting natural killer cells to CD19+ cells) and the angiogenesis inhibitor thalidomide. Monotherapy with either thalidomide or diabody caused an approximate 50% reduction in tumor growth rate. The combined treatment showed evidence for a synergistic effect resulting in a 74% reduction in median tumor size. In the combined treatment group, two of five animals had complete remissions of their s.c. tumor. These results suggest that a combination treatment with recombinant diabodies and angiogenesis inhibition represents a useful approach in cancer therapy. |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://journals.lww.com/anti-cancerdrugs/Fulltext/2004/10000/Combined_effect_of_recombinant_CD19_CD16_diabody.13.aspx |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1793916969 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Combined effect of recombinant CD19xCD16 diabody and thalidomide in a preclinical model of human B cell lymphoma / Schlenzka, Jana [VerfasserIn]; [October 2004] (Online-Ressource)
